BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, March 18, 2024
See today's BioWorld Asia
Home
» Epirus, Ranbaxy ink biosimilars deal for Asia, Africa
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Epirus, Ranbaxy ink biosimilars deal for Asia, Africa
Jan. 15, 2014
No Comments
HONG KONG – Epirus Switzerland GmbH expanded its focus on emerging markets via a new licensing deal with India’s largest maker of generics and biosimilars.
BioWorld Asia